- Home
- ALT
ALT
Altimmune Inc.
as 07-15-2025 3:30pm EST
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | GAITHERSBURG |
| Market Cap: | 397.4M | IPO Year: | N/A |
| Target Price: | $18.20 | AVG Volume (30 days): | 11.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.90 - $11.16 | Next Earning Date: | 08-07-2025 |
| Revenue: | $20,000 | Revenue Growth: | -95.12% |
| Revenue Growth (this year): | -89.19% | Revenue Growth (next year): | 1557547.90% |
Latest Altimmune Inc. News
ALT Breaking Stock News: Dive into ALT Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD)
Insider Monkey
7 days ago
Altimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in MASH Trial
MT Newswires
19 days ago
Altimmune Says Phase 2b Trial of Pemvidutide Shows 'Statistically Significant' MASH Resolution
GlobeNewswire
19 days ago
Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH
GlobeNewswire
20 days ago
Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26
GlobeNewswire
a month ago
Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association’s Scientific Sessions
GlobeNewswire
2 months ago
Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD)
TipRanks
2 months ago
Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension
Compare ALT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALT Altimmune Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.